| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). …
Over the last 12 months, insiders at Coya Therapeutics, Inc. have bought $0 and sold $0 worth of Coya Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Coya Therapeutics, Inc. have bought $55,007 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,800 shares for transaction amount of $12,934 was made by SNYDER DAVID S (Chief Financial Officer) on 2024‑11‑14.
| 2024-11-14 | SNYDER DAVID S | Chief Financial Officer | 1,800 0.0126% | $7.19 | $12,934 | -10.87% | ||
| 2024-11-13 | Swaminathan Arun | Chief Executive Officer | 5,000 0.0335% | $7.36 | $36,797 | -16.16% | ||
| 2024-11-11 | Swaminathan Arun | Chief Executive Officer | 5,000 0.0336% | $7.34 | $36,689 | -17.12% | ||
| 2024-11-11 | Grossman Fred | Chief Medical Officer | 2,710 0.0183% | $7.37 | $19,973 | -17.12% | ||
| 2023-08-22 | Lee Ann | director | 1,000 0.0104% | $3.62 | $3,620 | +94.16% | ||
| 2023-01-03 | Villalobos Anabella | director | 10,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | Lee Ann | director | 10,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | Hepner Adrian | Chief Medical Officer | 10,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | GOLDSTEIN DOV A MD | director | 10,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | Berman Howard | Chief Executive Officer | 10,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | SNYDER DAVID S | Chief Financial Officer | 7,000 – | $0 | $0 | -2.15% | ||
| 2023-01-03 | Garren Hideki | director | 2,000 – | $0 | $0 | -2.15% |
| Lee Ann | director | 17479 0.0745% | $54,359.69 | 2 | 0 | +94.16% |
| GOLDSTEIN DOV A MD | director | 10000 0.0426% | $31,100.00 | 1 | 0 | |
| Hepner Adrian | Chief Medical Officer | 10000 0.0426% | $31,100.00 | 1 | 0 | |
| Villalobos Anabella | director | 10000 0.0426% | $31,100.00 | 1 | 0 | |
| Berman Howard | Chief Executive Officer | 10000 0.0426% | $31,100.00 | 1 | 0 | |
| Swaminathan Arun | Chief Executive Officer | 10000 0.0426% | $31,100.00 | 2 | 0 | <0.0001% |
| SNYDER DAVID S | Chief Financial Officer | 8800 0.0375% | $27,368.00 | 2 | 0 | <0.0001% |
| Grossman Fred | Chief Medical Officer | 2710 0.0116% | $8,428.10 | 1 | 0 | <0.0001% |
| Garren Hideki | director | 2000 0.0085% | $6,220.00 | 1 | 0 |
$5,831,763 | 118 | -33.78% | $66.68M | |
$9,405,928 | 107 | 12.61% | $74.85M | |
$17,525,882 | 60 | 5.22% | $64.7M | |
$19,705,388 | 47 | 86.26% | $67.15M | |
$909,129 | 37 | 42.19% | $67.23M |
| Increased Positions | 49 | +175% | 4M | +74.77% |
| Decreased Positions | 11 | -39.29% | 379,990 | -7.96% |
| New Positions | 29 | New | 3M | New |
| Sold Out Positions | 7 | Sold Out | 196,667 | Sold Out |
| Total Postitions | 66 | +135.71% | 8M | +66.81% |
| Dme Capital Management, Lp | $9,302.00 | 7.84% | 1.65M | 0 | 0% | 2025-09-30 |
| Aigh Capital Management Llc | $6,247.00 | 5.27% | 1.11M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $4,726.00 | 3.98% | 836,393 | -4,078 | -0.48% | 2025-09-30 |
| Cm Management, Llc | $1,695.00 | 1.43% | 300,000 | +100,000 | +50% | 2025-09-30 |
| Geode Capital Management, Llc | $886.00 | 0.75% | 156,845 | -242 | -0.15% | 2025-09-30 |
| Dauntless Investment Group, Llc | $865.00 | 0.73% | 153,021 | +101,932 | +199.52% | 2025-09-30 |
| Blackrock, Inc. | $395.00 | 0.33% | 69,958 | +1,702 | +2.49% | 2025-09-30 |
| Citadel Advisors Llc | $369.00 | 0.31% | 65,240 | +22,120 | +51.3% | 2025-09-30 |
| State Street Corp | $272.00 | 0.23% | 48,100 | 0 | 0% | 2025-09-30 |
| Marshall Wace, Llp | $236.00 | 0.2% | 41,825 | +41,825 | New | 2025-09-30 |